EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Regenerx Biopharmaceuticals's enterprise value is $1.40 Mil.
Regenerx Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-1.36 Mil. Therefore, Regenerx Biopharmaceuticals's EV-to-EBITDA for today is -1.02.
The historical rank and industry rank for Regenerx Biopharmaceuticals's EV-to-EBITDA or its related term are showing as below:
RGRX's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.095 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Regenerx Biopharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's EV-to-EBITDA falls into.
Regenerx Biopharmaceuticals's current Enterprise Value is $1.40 Mil.
Regenerx Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Regenerx Biopharmaceuticals's PE Ratio for today is calculated as:
Regenerx Biopharmaceuticals's share price for today is $0.0014.
Regenerx Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.903.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Regenerx Biopharmaceuticals EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGRX has been successfully added to your 